Vanguard Group’s Tonix Pharmaceuticals TNXP Stock Holding History

Vanguard Group’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$10.5M	Buy	673,605 +116,648	+21%	+$2.15M	﹤0.01%	2939
2025 Q3	$13.5M	Buy	556,957 +392,225	+238%	+$14.6M	﹤0.01%	2814
2025 Q2	$5.93M	Buy	164,732 +73,236	+80%	+$1.92M	﹤0.01%	3154
2025 Q1	$1.64M	Buy	+91,496	New	+$1.85M	﹤0.01%	3558
2024 Q3	–	Sell	-254	Closed	-$17.7K	–	4384
2024 Q2	$17.7K	Buy	254 +88	+53%	+$39.9K	﹤0.01%	4363
2024 Q1	$98.7K	Buy	166 +39	+31%	+$42K	﹤0.01%	4245
2023 Q4	$163K	Buy	127 +3	+2%	+$4.83K	﹤0.01%	4246
2023 Q3	$217K	Sell	124 -1	-0.8%	-$3.65K	﹤0.01%	4243
2023 Q2	$630K	Buy	125 +4	+3%	+$30.3K	﹤0.01%	4051
2023 Q1	$1.44M	Buy	121 +72	+147%	+$1.24M	﹤0.01%	3792
2022 Q4	$380K	Buy	49 +6	+14%	+$51.8K	﹤0.01%	4176
2022 Q3	$459K	Buy	43 +6	+16%	+$147K	﹤0.01%	4240
2022 Q2	$1.16M	Buy	37 +8	+28%	+$590K	﹤0.01%	4039
2022 Q1	$4.21M	Sell	29 -2	-6%	-$306K	﹤0.01%	3615
2021 Q4	$7.02M	Buy	31 +6	+24%	+$1.91M	﹤0.01%	3426
2021 Q3	$9.62M	Hold	25	–	–	﹤0.01%	3263
2021 Q2	$17.5M	Buy	25 +2	+9%	+$1.47M	﹤0.01%	2917
2021 Q1	$18.8M	Buy	23 +20	+667%	+$15.3M	﹤0.01%	2815
2020 Q4	$1.23M	Buy	3 +2	+200%	+$820K	﹤0.01%	3782
2020 Q3	$433K	Hold	1	–	–	﹤0.01%	3839
2020 Q2	$234K	Hold	1	–	–	﹤0.01%	3906
2020 Q1	$272K	Buy	+1	New	+$663K	﹤0.01%	3813
2019 Q4	–	Hold	0	–	-$34K	–	4136
2019 Q3	–	Hold	0	–	–	–	4106
2019 Q2	–	Hold	0	–	–	–	4038
2018 Q4	–	Hold	0	–	-$119K	–	4158
2018 Q3	–	Hold	0	–	–	–	4056
2018 Q2	–	Hold	0	–	–	–	3693
2018 Q1	–	Hold	0	–	–	–	3758
2017 Q4	–	Hold	0	–	–	–	3710
2017 Q3	–	Hold	0	–	–	–	3672
2017 Q2	–	Hold	0	–	–	–	3620
2017 Q1	–	Hold	0	–	–	–	3689
2016 Q4	–	Hold	0	–	–	–	3857
2016 Q3	–	Hold	0	–	–	–	3744
2016 Q2	–	Hold	0	–	–	–	3503
2016 Q1	–	Hold	0	–	–	–	3442
2015 Q4	–	Hold	0	–	–	–	3114
2015 Q3	–	Hold	0	–	–	–	3296
2015 Q2	–	Hold	0	–	–	–	3203
2015 Q1	–	Hold	0	–	–	–	3360
2014 Q4	–	Hold	0	–	–	–	3406
2014 Q3	–	Hold	0	–	–	–	3348
2014 Q2	–	Hold	0	–	–	–	3095
2014 Q1	–	Hold	0	–	–	–	3215
2013 Q4	–	Hold	0	–	–	–	3650

Other funds holding TNXP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group's TNXP Position: Q4 2025 in Review

Vanguard Group increased its Tonix Pharmaceuticals (TNXP) stake by 21% in Q4 2025, buying an estimated $2.15M and bringing the position to 673,605 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2939.

Vanguard Group first reported a position in TNXP in Q1 2020 and has held it in 22 quarters since. The position peaked at $18.8M in Q1 2021. 70 funds tracked by Wall St. Rank hold TNXP as of Q4 2025.

Vanguard Group held 673,605 shares of Tonix Pharmaceuticals worth $10.5M as of Q4 2025.
Vanguard Group bought 116,648 Tonix Pharmaceuticals shares in Q4 2025, an estimated $2.15M.
Tonix Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2939 holding.
Vanguard Group first reported a position in Tonix Pharmaceuticals in Q1 2020 and has held it in 22 quarters since.
Vanguard Group's Tonix Pharmaceuticals position peaked at $18.8M in Q1 2021.
70 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.